A randomized controlled trial investigating the effect of Pycnogenol and Bacopa CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: the Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910)

Nutrition Journal

Andrew B Scholey⁵  Dennis Chang¹  Kevin Croft⁴  Andrew Pipingas⁵  Keith Wesnes²  David Camfield⁵  Rebecca King⁵  Karen Nolidin⁵  Stephen Myers³  Vanessa Cropley⁶  Matthew P Pase⁵  Con K Stough⁵ 

[1] Complemed, NICM, University of Western Sydney, Australia;CDR, Bracket, Goring-On-Thames, England;Southern Cross University, Lismore, Australia;School of Medicine and Pharmacology, University of Western Australia, Australia;Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, Australia;Melbourne Neuropsychiatry Centre, The University of Melbourne, Australia

关键词: RCT;    Ageing;    Cognition;    Cognitive;    Dementia;    Brain;    Pine bark;    CDRI08;    Bacopa;    Pycnogenol;   

Others  :  825836
DOI  :  10.1186/1475-2891-11-11

 received in 2011-11-10, accepted in 2012-03-06,  发布年份 2012

【 摘 要 】

Background

One of the major challenges associated with our ageing population is the increasing incidence of age-associated cognitive decline, which has significant implications for an individual's ability to lead a productive and fulfilling life. In pure economic terms the costs of ageing reflects decreased productivity and engagement with the workforce. The maintenance of brain health underpinning intact cognition is a key factor to maintaining a positive, engaged, and productive lifestyle. In light of this, the role of diet, including supplementation with nutritional and even pharmacological interventions capable of ameliorating the neurocognitive changes that occur with age constitute vital areas of research.

Methods

In order to reduce cognitive ageing, the ARC longevity intervention (ARCLI) was developed to examine the effects of two promising natural pharmacologically active supplements on cognitive performance. ARCLI is a randomized, placebo-controlled, double-blind, 3-arm clinical trial in which 465 participants will be randomized to receive an extract of Bacopa monnieri (CDRI08 300 mg/day), Pycnogenol (150 mg/day), or placebo daily for 12 months. Participants will be tested at baseline and then at 3, 6 and 12 months post-randomization on a wide battery of cognitive, neuropsychological and mood measures, cardiovascular (brachial and aortic systolic and diastolic blood pressures as well as arterial stiffness), biochemical (assays to measure inflammation, oxidative stress and safety) as well as genetic assessments (telomere length and several Single Nucleotide Polymorphisms). The primary aim is to investigate the effects of these supplements on cognitive performance. The secondary aims are to explore the time-course of cognitive enhancement as well as potential cardiovascular and biochemical mechanisms underpinning cognitive enhancement over the 12 months of administration.

ARCLI will represent one of the largest and most comprehensive experimental clinical trials in which supplements are administered to elderly participants. Results from ARCLI may help develop novel preventative health practices and nutritional/pharmacological targets in the elderly for cognitive and brain health.

Trial registration

Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12611000487910

【 授权许可】

   
2012 Stough et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Economic Implications of an Ageing Australia Productivity Commission Research Report 2005.
• [2]Christensen H, Kumar R: Cognitive Changes and the Ageing Brain. In The Ageing Brain. Edited by Sachdev PS. Lisse: Swets & Zeitlinger, B.V; 2003:75-96.
• [3]Looi J, Sachdev PS: Structural Neuroimaging of the Ageing Brain. In The Ageing Brain. Edited by Sachdev PS. Lisse: Swets & Zeitlinger; 2003:49-62.
• [4]MacLullich AMJ, Ferguson KJ, Deary IJ, Seckl JR, Starr JM, Wardlaw JM: Intracranial capacity and brain volumes are associated with cognition in healthy elderly men. Neurology 2002, 59(2):169-174.
• [5]Braak H, Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18(4):351-357.
• [6]Slater TF: Free-radical mechanisms in tissue injury. Biochemical Journal 1984, 222(1):1-15.
• [7]Packer L: Free radical scavengers and antioxidants in prophylaxy and treatment of brain diseases. In Free Radicals in the Brain. Edited by Packer L, Prilipko L, Christen Y. New York. Springer-Verlag; 1992.
• [8]Papa S, Skulachev VP: Reactive oxygen species, mitochondria, apoptosis and aging. Molecular and Cellular Biochemistry 1997, 174(1-2):305-319.
• [9]Artur Y, Herbeth B, Guémouri L, Lecomte E, Jeandel C, Siest G: Age-related variations of enzymatic defenses against free radicals and peroxides. EXS 1992, 62:359-367.
• [10]Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262(5134):689-695.
• [11]Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N: Oxidative damage in Alzheimer's [6]. Nature 1996, 382(6587):120-121.
• [12]Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS: Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proceedings of the National Academy of Sciences of the USA 1996, 93(10):4765-4769.
• [13]Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR: Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proceedings of the National Academy of Sciences of the USA 1991, 88(23):10540-10543.
• [14]Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine 1997, 336(17):1216-1222.
• [15]Socci DJ, Crandall BM, Arendash GW: Chronic antioxidant treatment improves the cognitive performance of aged rats. Brain Research 1995, 693(1-2):88-94.
• [16]Goodwin JS, Goodwin JM, Garry PJ: Association between nutritional status and cognitive functioning in a healthy elderly population. Journal of the American Medical Association 1983, 249(21):2917-2921.
• [17]Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000, 54(6):1265-1272.
• [18]Srám RJ, Binková B, Topinka J, Kotěsovec F, Fojtíková I, Hanel I, Klaschka J, Kocisóvá J, Prosek M, Machálek J: Effect of antioxidant supplementation in an elderly population. Basic life sciences 1993, 61:459-477.
• [19]Packer L, Rimbach G, Virgili F: Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (pinus maritima) bark, pycnogenol. Free Radical Biology and Medicine 1999, 27(5-6):704-724.
• [20]Rohdewald P: A review of the French maritime pine bark extract (Pycnogenol®), a herbal medication with a diverse clinical pharmacology. International Journal of Clinical Pharmacology and Therapeutics 2002, 40(4):158-168.
• [21]Wei ZH, Peng QL, Lau BHS: Pycnogenol enhances endothelial cell antioxidant defenses. Redox Report 1997, 3(4):219-224.
• [22]Ishige K, Schubert D, Sagara Y: Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radical Biology and Medicine 2001, 30(4):433-446.
• [23]Kobayashi MS, Han D, Packer L: Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radical Research 2000, 32(2):115-124.
• [24]Liu F, Lau BHS, Peng Q, Shah V: Pycnogenol protects vascular endothelial cells from α-amyloid-induced injury. Biological and Pharmaceutical Bulletin 2000, 23(6):735-737.
• [25]Peng QL, Buz'Zard AR, Lau BHS: Pycnogenol® protects neurons from amyloid-β peptide-induced apoptosis. Molecular Brain Research 2002, 104(1-2):55-65.
• [26]Liu FJ, Zhang YX, Lau BHS: Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice. Cellular and Molecular Life Sciences 1998, 54(10):1168-1172.
• [27]Devaraj S, Vega-López S, Kaul N, Schönlau F, Rohdewald P, Jialal I: Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002, 37(10):931-934.
• [28]Prior RL, Cao G: In vivo total antioxidant capacity: Comparison of different analytical methods. Free Radical Biology and Medicine 1999, 27(11-12):1173-1181.
• [29]Russo A, Borrelli F: Bacopa monniera, a reputed nootropic plant: An overview. Phytomedicine 2005, 12(4):305-317.
• [30]Singh HK, Dharwan BN: Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera linn (Brahmi). Indian Journal of Pharmacology 1997, 29:S359-S365.
• [31]Agrawal A: A comparative study of psychotropic drugs and bio-feedback therapy in the prevention and management of psychosomatic disorder. In Thesis. Varanasi: Banaras Hindu University; 1993.
• [32]Bhattacharya SK, Kumar A, Ghosal S: Effect of Bacopa monniera on animal models of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. Research Communications in Pharmacology and Toxicology 1999, 4(3&4):1-12.
• [33]Jain SK: Ethnobotany and research on medicinal plants in India. Ciba Found Symp 1994, 185:153-164. discussion 164-158
• [34]Bhattacharya S, Ghosal S: Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental study. Phytomedicine 1998, 5(2):77-82.
• [35]Sairam K, Dorababu M, Goel RK, Bhattacharya SK: Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats. Phytomedicine 2002, 9(3):207-211.
• [36]Dar A, Channa S: Calcium antagonistic activity of Bacopa monniera on vascular and intestinal smooth muscles of rabbit and guinea-pig. J Ethnopharmacol 1999, 66(2):167-174.
• [37]Rai D, Bhatia G, Palit G, Pal R, Singh S, Singh HK: Adaptogenic effect of Bacopa monniera (Brahmi). Pharmacol Biochem Behav 2003, 75(4):823-830.
• [38]Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S: Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res 2000, 14(3):174-179.
• [39]Russo A, Borrelli F, Campisi A, Acquaviva R, Raciti G, Vanella A: Nitric oxide-related toxicity in cultured astrocytes: effect of Bacopa monniera. Life Sci 2003, 73(12):1517-1526.
• [40]Tripathi YB, Chaurasia S, Tripathi E, Upadhyay A, Dubey GP: Bacopa monniera Linn. as an antioxidant: mechanism of action. Indian J Exp Biol 1996, 34(6):523-526.
• [41]Holcomb LA, Dhanasekaran M, Hitt AR, Young KA, Riggs M, Manyam BV: Bacopa monniera extract reduces amyloid levels in PSAPP mice. J Alzheimers Dis 2006, 9(3):243-251.
• [42]Ryan J, Croft K, Mori T, Wesnes K, Spong J, Downey L, Kure C, Lloyd J, Stough C: An examination of the effects of the antioxidant Pycnogenol® on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. Journal of Psychopharmacology 2008, 22(5):553-562.
• [43]Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C: The cognitive enhancing effects of Bacopa monneiri: A systematic review of randomized, controlled human clinical trials. Journal of Alternative and Complementary Medicine, in press.
• [44]Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, Wesnes K, Nathan PJ: Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 Day double-blind placebo-controlled randomized trial. Phytotherapy Research 2008, 22(12):1629-1634.
• [45]Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ: The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 2001, 156(4):481-484.
• [46]Pipingas A, Harris E, Tournier E, King R, Kras M, Stough CK: Assessing the efficacy of nutraceutical interventions on cognitive functioning in the elderly. Current Topics in Nutraceutical Research 2010, 8(2-3):79-87.
• [47]Pipingas A, Silberstein RB, Vitetta L, Van Rooy C, Harris EV, Young JM, Frampton CM, Sali A, Nastasi J: Improved cognitive performance after dietary supplementation with a Pinus radiata bark extract formulation. Phytotherapy Research 2008, 22(9):1168-1174.
• [48]Scholey AB, French SJ, Morris PJ, Kennedy DO, Milne AL, Haskell CF: Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort. Journal of Psychopharmacology 2010, 24(10):1505-1514.
• [49]Folstein MF, Folstein SE, McHugh PR: 'Mini mental state'. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12(3):189-198.
• [50]Deary IJ, Stough C: Intelligence and Inspection Time: Achievements, Prospects, and Problems. American Psychologist 1996, 51(6):599-608.
• [51]Jensen AR: The theory of intelligence and its measurement. Intelligence 2011, 39(4):171-177.
• [52]Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Archives of general psychiatry 1961, 4:561-571.
• [53]Spielberger CD, Gorsuch RL, Lushene RE: Manual for the State-Trait Anxiety Inventory. In Palo Alto. California: Consulting Psychologists Press; 1970.
• [54]McNair DM, Lorr M, Droppelman LM: Profile of Mood States. San Diego: Educational and Industrial Testing Service; 1970.
• [55]Bond A, Lader M: Use of analog scales in rating subjective feelings. British Journal of Medical Psychology 1974, 47:211-218.
• [56]Goldberg D: General Health Questionnaire (GHQ-12). Windsor, England: NFER-Nelson; 1992.
• [57]Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP: Development of a fatigue scale. Journal of Psychosomatic Research 1993, 37(2):147-153.
• [58]Parrott AC, Hindmarch I: Factor analysis of a sleep evaluation questionnaire. Psychological Medicine 1978, 8(2):325-329.
• [59]Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C: Prediction of cardiovascular events and all-cause mortality with central haemodynamics: A systematic review and meta-analysis. European Heart Journal 2010, 31(15):1865-1871.
• [60]Vlachopoulos C, Aznaouridis K, Stefanadis C: Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness. A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology 2010, 55(13):1318-1327.
• [61]Pase MP, Pipingas A, Kras M, Nolidin K, Gibbs AL, Wesnes KA, Scholey AB, Stough C: Healthy middle-aged individuals are vulnerable to cognitive deficits as a result of increased arterial stiffness. Journal of Hypertension 2010, 28(8):1724-1729.
• [62]Pase MP, Herbert A, Grima NA, Pipingas A, O' Rourke MF: Arterial stiffness as a cause of cognitive decline and dementia: A systematic review and meta-analysis. Internal Medicine Journal, in press.
• [63]Pase MP, Grima NA, Sarris J: The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. American Journal of Clinical Nutrition 2011., 93(446-454)
• [64]Tanaka H, Safar ME: Influence of lifestyle modification on arterial stiffness and wave reflections. American Journal of Hypertension 2005, 18(1):137-144.
• [65]Pase MP, Grima NA, Sarris J: Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. British Journal of Nutrition 2011, 106(07):974-980.
• [66]Messier C, Tsiakas M, Gagnon M, Desrochers A, Awad N: Effect of age and glucoregulation on cognitive performance. Neurobiology of Aging 2003, 24(7):985-1003.
• [67]Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43(8):1467-1472.
• [68]Dik MG, Jonker C, Comijs HC, Bouter LM, Twisk JWR, Van Kamp GJ, Deeg DJH: Memory complaints and APOE-ε4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001, 57(12):2217-2222.